Evidence map›Paper›PMID 31197453›Full record

ArticleJournal of cancer research and clinical oncology2019

Aberrant expression of Sec61α in esophageal cancers.

Kai Bachmann, Maximillian Bockhorn, Oliver Mann, Florian Gebauer, Marco Blessmann, Jakob Robert Izbicki, Katharina Grupp

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. HighOpen medicine (Warsaw, Poland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kai BachmannGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Maximillian BockhornGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Oliver MannGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Florian GebauerGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Marco BlessmannDepartment of Plastic, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Jakob Robert IzbickiGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Katharina GruppGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. k.grupp@uke.de.ORCID http://orcid.org/0000-0003-2849-3743

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe heterotrimeric Sec61α translocon complex is topological located in the membrane of the endoplasmic reticulum (ER) and allows protein transport and calcium across the membrane. Recently, aberrant expression of Sec proteins was linked to carcinogenesis and prognosis of patients. MATERIALS AND

methodsHere, we analysed the role of Sec61α in esophageal cancer, and we analysed Sec61α staining on a tissue microarray containing more than 600 esophageal cancer specimens by immunohistochemistry.

resultsSec61α staining was always strong in benign esophagus, but was only found in 5% of interpretable esophageal adenocarcinomas (EACs) and 14.5% of squamous cell carcinomas (ESCCs). Reduced Sec61α staining was not strongly linked to tumor phenotype in both subgroups of esophageal cancers and was unrelated to clinical outcome of patients (EACs: p = 0.8051 and ESCCs: p = 0.2751).

conclusionsThus, Sec61α measurement has not an additional prognostic benefit for the patients.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansImmunohistochemistryMaleMiddle AgedPredictive Value of TestsPrognosisSEC Translocation ChannelsTissue Array AnalysisSEC61A1 protein, humanSEC Translocation ChannelsEsophageal cancerSec61αTissue microarray

Identifiers

PMID31197453
PMCPMC11810308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.